Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 189 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Visual Impairment Clear all
Recruiting Not applicable Interventional

Visual Influences on Vestibular Adaptation

NCT07380256
View directory record Official record
Conditions
Vestibular Hypofunction, Binocular Vision Abnormalities, Reduced Vision
Interventions
StableEyes: Incremental Vestibulo-Ocular Reflex Adaptation (IVA)
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 22, 2026, 12:46 PM EDT
Completed Not applicable Interventional

Diabetic Retinopathy Tethered Augmented Reality With Eye4 Study

NCT05491746
View directory record Official record
Conditions
Diabetic Retinopathy, Low Vision
Interventions
Eye4, Placebo
Device · Other
Lead sponsor
Eyedaptic
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Jul 22, 2026, 12:46 PM EDT
Terminated No phase listed Observational

Intraocular Pressure During Prone Spinal Surgery

NCT00176722
View directory record Official record
Conditions
Spine Surgery, Vision Impairment
Interventions
table tilt
Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Jul 22, 2026, 12:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of "Smart Wheelchairs" to Provide Independent Mobility to Visual and Mobility Impairments

NCT00333762
View directory record Official record
Conditions
Blindness, Spinal Cord Injury
Interventions
Smart Power Assistance Module (SPAM), Smart Wheelchair Component System (SWCS)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
2
States / cities
Decatur, Georgia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Jul 22, 2026, 12:46 PM EDT
Not listed Not applicable Interventional

Telescope Exchange Study

NCT03011554
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Implantable Miniature Telescope (IMT)
Device
Lead sponsor
VisionCare, Inc.
Industry
Eligibility
65 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Jul 22, 2026, 12:46 PM EDT
Completed Phase 1 Interventional

A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME

NCT02193113
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KVD001 Injection
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Beverly Hills, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 22, 2026, 12:46 PM EDT
Terminated Phase 4 Interventional Results available

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

NCT04707625
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept Ophthalmic
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 22, 2026, 12:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

First-Sight Refractive Error Correction in the Developing World

NCT01598818
View directory record Official record
Conditions
Vision Loss
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
7 Years to 50 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Jul 22, 2026, 12:46 PM EDT
Completed Not applicable Interventional

Low Vision Occupational Therapy in Parkinson's Disease

NCT04127838
View directory record Official record
Conditions
Parkinson Disease
Interventions
Low Vision Occupational Therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Jul 22, 2026, 12:46 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Statistical Learning as a Novel Intervention for Cortical Blindness

NCT06578117
View directory record Official record
Conditions
Stroke, Ischemic, Hemianopia, Homonymous, Hemianopsia, Occipital Lobe Infarct, Visual Field Defect, Peripheral, Vision Loss Partial, Quadrantanopia, Stroke Hemorrhagic
Interventions
Vision Training and Learning Task
Device
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 22, 2026, 12:46 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

NCT04638660
View directory record Official record
Conditions
Dim Light Vision Disturbances
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle (Placebo)
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Newport Beach, California • Petaluma, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 22, 2026, 12:46 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 12:46 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

NCT03927690
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
LKA651, Lucentis
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Jul 22, 2026, 12:46 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study

NCT05045703
View directory record Official record
Conditions
Choroideremia
Interventions
Vitamin A palmitate
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
15 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jul 22, 2026, 12:46 PM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

NCT04423718
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Jul 22, 2026, 12:46 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Eye Health Intervention Study in Upper Manhattan

NCT06112431
View directory record Official record
Conditions
Glaucoma, Suspect, Diabetic Retinopathy, Cataract, Refractive Errors, Vision Impairment and Blindness
Interventions
Intervention, Usual Care
Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 12:46 PM EDT
Completed Phase 2 Interventional

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

NCT00088283
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2007 · Synced Jul 22, 2026, 12:46 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Valproate for the Treatment of Residual Amblyopia

NCT07226141
View directory record Official record
Conditions
Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
Interventions
Valproate, Placebo, Patch
Drug · Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 22, 2026, 12:46 PM EDT
Completed Not applicable Interventional

Problem Solving Training and Low Vision Rehabilitation

NCT00545220
View directory record Official record
Conditions
Low Vision
Interventions
problem-solving training, sham intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Jul 22, 2026, 12:46 PM EDT
Completed No phase listed Observational

Diabetic Retinopathy and Sickle Trait

NCT00720317
View directory record Official record
Conditions
Diabetic Retinopathy, Sickle Cell Trait
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Jul 22, 2026, 12:46 PM EDT
Active, not recruiting No phase listed Observational

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

NCT06162585
View directory record Official record
Conditions
Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions
Gene Therapy product-MCO-010
Biological
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Jul 22, 2026, 12:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ability of Patients With Low Vision to Properly Instill Eye Drops

NCT00760240
View directory record Official record
Conditions
Glaucoma, Retinal Pathology
Interventions
Not listed
Lead sponsor
Mid-Atlantic Glaucoma Experts
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2010 · Synced Jul 22, 2026, 12:46 PM EDT
Completed Not applicable Interventional

Nonvisual Foot Inspection for People With Visual Impairment

NCT01822717
View directory record Official record
Conditions
Diabetes, Visual Impairment
Interventions
Nonvisual foot inspection, Usual Care
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 12:46 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

NCT06349759
View directory record Official record
Conditions
Mesopic Vision, Night Vision Loss
Interventions
phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, Placebo
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
25
States / cities
Pheonix, Arizona • Scottsdale, Arizona • Bakersfield, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 22, 2026, 12:46 PM EDT